概括
自20世纪50年代以来使用的甲托雷克萨特,在低剂量下有效降低炎症. 这使得它成为各种炎症性皮肤疾病的宝贵治疗方法.
科学领域:
- 药理学 药理学是指药理学的学科.
- 皮肤病学 皮肤病学
- 免疫学 免疫学 免疫学
背景情况:
- 自20世纪50年代以来,甲基已被用于医疗治疗.
- 最初,高剂量用于儿科癌症治疗.
- 低剂量甲状腺素因其抗炎性质而闻名.
研究的目的:
- 探索甲状腺素在治疗皮肤病的应用.
- 为了突出低剂量甲状腺在治疗炎症性皮肤疾病中的作用.
主要方法:
- 复习甲铁酸盐的历史和当前治疗应用.
- 在减少炎症方面分析甲索特酸的作用机制.
- 检查支持其在皮肤病学中的使用的临床证据.
主要成果:
- 自20世纪中叶以来,美索特雷克萨特在治疗各种疾病中的有效性已经得到证实.
- 低剂量的甲状腺素有效地减轻炎症.
- 炎症是许多皮肤疾病的发病的一个关键因素.
结论:
- 低剂量甲状腺素是一种可行的治疗选择,用于炎症性皮肤病.
- 甲状腺素的抗炎作用支持其在治疗皮肤疾病中的有用性.
相关概念视频
Phase II Reactions: Methylation Reactions
220
Methylation is a phase II biotransformation process involving the attachment of a methyl group to a substrate. Enzymes known as methyltransferases orchestrate this reaction.
The mechanism of methylation unfolds in two stages. The first stage sees a methyltransferase enzyme facilitating the transfer of a methyl group from S-adenosylmethionine (SAM) to the substrate, forming S-adenosylhomocysteine (SAH). The second stage involves further metabolism of SAH into homocysteine, which can be recycled...
The mechanism of methylation unfolds in two stages. The first stage sees a methyltransferase enzyme facilitating the transfer of a methyl group from S-adenosylmethionine (SAM) to the substrate, forming S-adenosylhomocysteine (SAH). The second stage involves further metabolism of SAH into homocysteine, which can be recycled...
220
Drugs for Treatment of Crohn's Disease in IBD Using Immunomodulatory Agents
186
Crohn's disease is an inflammatory bowel disorder marked by chronic inflammation of the GI tract. Various treatment strategies for Crohn's disease are employed, such as immunomodulatory agents, glucocorticoids, and biologics or anti-TNF therapy. Azathioprine (Imuran), a commonly used immunomodulatory drug for Crohn's disease, is converted in the body to mercaptopurine, which inhibits purine biosynthesis and cell proliferation. Both are utilized in severe cases of Inflammatory Bowel...
186
Drugs that Destabilize Microtubules
2.0K
Microtubules are dynamic structures and can be regulated by microtubule targeting agents (MTAs). Microtubule destabilizing drugs are a class of MTAs that destabilize and prevent microtubules' polymerization. Both natural and synthetic chemicals can be found under this class of drugs. Vincristine and vinblastine, two vinca alkaloids, and colchicine were among the first to be discovered. These drugs can affect cells in various ways, either by inducing a change in cell morphology, preventing...
2.0K
Treatment Resistant Cancers
3.3K
Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
3.3K
Drugs that Stabilize Microtubules
2.1K
Microtubules are dynamic structures that undergo cycles of catastrophe and rescue. The microtubules play a central role in cell division by forming the spindle apparatus for segregating the chromosomes. This makes them ideal targets for regulating dividing cells in tumors and malignant cancer cells. Microtubule stabilizing drugs help stabilize the microtubule formation and promote its polymerization. Paclitaxel was the first microtubule stabilizing agent used as anticancer drug in chemotherapy...
2.1K
Targeted Cancer Therapies
7.7K
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
There are several types of targeted therapies against...
7.7K


